Image: Pharma Deutschland

Tuesday, December 2, 2025

Pharma Germany Appoints Three New Board Members to Strengthen Industry Representation

Pharma Germany has strategically expanded its board at the 71st General Assembly. On 25 November 2025, three new leaders were appointed to the governing body: Hatice Camdere (Amgen GmbH), Susanne Lamminger (Hexal AG / Sandoz), and Christian Thams (Johnson & Johnson Innovative Medicine).

With the election of these three executives, the association underscores its commitment to representing the diverse pharmaceutical sector even more effectively. Chairman Jörg Wieczorek stated: “By expanding the board, we are strengthening the committee with dedicated individuals whose expertise and deep understanding of both the industry and political framework will further enhance our positioning. Our goal is to represent the diverse sector and its concerns to the fullest extent and to contribute to making Germany’s pharmaceutical landscape stronger, future-proof, and more resilient.”

During the assembly, the board was expanded from 17 to 18 members. At the same time, the association bid farewell to two long-standing board members: Dr. Theresa von Fugler (formerly Opella Germany / A. Nattermann & Cie. GmbH) and Christian Hilmer (Johnson & Johnson), who have stepped down from their roles.

The new appointments mark a significant signal for a robust and forward-looking strategic orientation of the German pharmaceutical industry.